Intellia's stock jumps as crispr therapy moves into phase 2 clinical trial

Shares of Intellia Therapeutics Inc. NTLA, +1.44% rallied about 10% in premarket trading on Thursday after the company said the Food and Drug Administ...

March 2, 2023, 8:09 am

First look at global x hydrogen etf

Although there are a lot of options for investors in the clean energy space, it is quite limited for investors in the hydrogen space. The industry is ...

March 1, 2023, 3:18 pm

Bae pipeline predicted to convert into new phase of growth - barclays

BAE Systems PLC (LSE:BA.) was one of the best performing of London's blue-chips stocks last year and Barclays is predicting there could be a new phas...

March 1, 2023, 11:38 am

Spc nickel commences infill drill program at recently consolidated west graham-crean hill 3 project

SPC Nickel Corp (TSX-V:SPC, OTC:SPCNF) has updated investors on the progress at its recently consolidated West Grahan-Crean Hill 3 project, including ...

March 1, 2023, 8:56 am

Ecb's villeroy: it would be desirable to reach terminal rate by the summer

• If not, by September at the latest
• Now entering a new phas...

  March 1, 2023, 8:45 am

Why is okyo pharma (okyo) stock down 31% today?

OKYO Pharma (NASDAQ: OKYO ) stock is taking a beating on Wednesday despite recent progress toward a clinical trial. The latest news from OKYO Pharma i...

March 1, 2023, 8:19 am

Power nickel continues to report new productive results from phase 2 drill program at nisk project

Power Nickel Inc (TSX-V:PNPN) has said it continues to report new productive results from its phase 2 ...

March 1, 2023, 6:46 am

Sequana medical announces positive results from chihuahua, phase 1 clinical trial of second-generation dsr product for congestive heart failure

PRESS RELEASE phase 1 clinical trial (CHIHUAHUA) demonstrates that single dose of second-generation DSR...

March 1, 2023, 6:14 am

Passage bio undervalued on price, long-term gene therapy prospects

Passage Bio's most advanced gene therapy reported good early phase 1 data. Over $200 million in cash sh...

February 28, 2023, 11:39 pm

Trading technologies integrates bantix’s options analytical platform, quikstrike

Christen Harvey, VP Strategic Partnerships of TT, said: Our alliance with Bantix is the latest strategic partnership we’ve forged with a best-in-bre...

February 28, 2023, 3:23 pm

Shiftcarbon details us$5m engagement with solutions by stc; initial roll-out of focused footprint to marine industry

ShiftCarbon (CSE:SHFT) CEO Wayne Lloyd joined Proactive's Stephen Gunnion with details of the company's first revenue-generating engagement with Saud...

February 28, 2023, 1:50 pm

Aim immunotech announces phase 2 study of ampligen® for the treatment of pancreatic cancer is open and recruiting patients

Ongoing efforts to open additional clinical sites for recruitment at premier cancer centers across the U.S. and Europe are in progress to facilitate p...

February 28, 2023, 1:45 pm

Bp & partners advance gta project to next evaluation phase

The development concept for the second phase of the BP-operated Greater Tortue Ahmeyim liquefied natura...

February 28, 2023, 9:48 am

Okyo pharma making final preparations for upcoming clinical trial of dry eye disease drug

OKYO Pharma Ltd (LSE:OKYO, NASDAQ:OKYO), the ophthalmology-focused bio-pharma company, has announced that its GMP-packaged drug has cleared customs in...

February 28, 2023, 2:38 am

Medicenna: multiple catalysts ahead in 2023

Medicenna is testing MDNA11, an IL-2 superkine, with potential in various cancer types, in a phase 1/2 ...

February 28, 2023, 2:31 am

Dream-hf phase 3 trial results for mesoblast cell therapy in heart failure published in journal of the american college of cardiology (jacc)

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced publication of the...

February 27, 2023, 11:29 pm

Ocugen, inc. announces submission of investigational new drug application with u.s. fda to initiate a phase 1 clinical trial evaluating ocu200 for the treatment of diabetic macular edema

MALVERN, Pa., Feb. 27, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on d...

February 27, 2023, 10:57 pm

Lightning round: this is boeing's time if they don't screw it up

Mad Money host Jim Cramer weighs in on all manner of stocks, including Accenture, Boeing, Biogen, Union Pacific, Meta, Nokia and En...

February 27, 2023, 7:43 pm

Palantir: why i am still in

Mr. Market rushed to buy Palantir's "Profitability" cover story. However, the company is not operationally profitable yet, but we should get there soo...

February 27, 2023, 3:26 pm

Why is enphase energy (enph) stock up 5% today?

Amid a modestly positive Monday afternoon, solar technology specialist Enphase Energy (NASDAQ: ENPH ) e...

February 27, 2023, 3:25 pm